References
- Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20–32.
- Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple mieloma patients. Blood 2002:99:3163–3168.
- Feyler S, Rawstron A, Jackson GH, et al. Thalidomide maintenance following high dose therapy in multiple myeloma: a UK myeloma forum phase II study. Blood 2007;39:429–433.
- Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–1791.
- McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–1781.
- Palumbo A, Hajek R, Delforge M, et al. Continous treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366: 1759–1769.
- Rajkumar SV. Lenalidomide maintenance - perils of a premature denouement. Nat Rev Clin Oncol 2012;9:372–374.
- Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukaemia in children treated with epidophyllotoxins for acute lymphoblastic leukaemia. N Engl J Med 1991;325:1682–1687.
- Zuna J, Cavé H, Eckert C, et al. Childhood secondary ALL after ALL treatment. Leukemia 2007;21:1431–1435.
- Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012; 120:1597–1600.
- Larson RA. Acute lymphoblastic leukaemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program 2005: 131–136.
- Agostino NM, Ahmed D, Popescu D, et al. Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of literature. Int J Clin Exp Pathol 2011;4:322–326.
- Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low or intermediate 1 MDS with del(5q): a comparative analysis. Leukemia 2012 Dec 21. [Epub ahead of print]
- Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013;31:584–591.
- Blum W, Kisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010;28:4919–4925.
- Garrison LP Jr, Wang ST, Huang H, et al. The cost effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist 2013;18:27–36.
- Delforge M, Dhawan R, Robinson D Jr, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs MP: results from the Vista trial. Eur J Hematol 2012;89:16–27.
- Dimopoulos M, Delforge M, Hajek R, et al. Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica 2012 Dec 14. [Epub ahead of print].
- Rajkumar SV. Doublets, triplets or quatruplets of novel agents in newly diagnosed myeloma. Hematology Am Soc Hematol Educ Program 2012:354–361.